1 / 7

GUSTO IV ACS: Trial Design

GUSTO IV ACS: Trial Design. Abciximab versus placebo in very high-risk patients with non-ST elevation acute coronary syndromes: ST ¯ > 0.5 mm or elevated troponin I Medical management for at least 60 hours If a patient underwent PCI within 30 days, abciximab permitted in all patients

lotus
Télécharger la présentation

GUSTO IV ACS: Trial Design

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. GUSTO IV ACS: Trial Design • Abciximab versus placebo in very high-risk patients with non-ST elevation acute coronary syndromes: • ST¯ > 0.5 mm or • elevated troponin I • Medical management for at least 60 hours • If a patient underwent PCI within 30 days, abciximab permitted in all patients • Primary Endpoint: 30 day death / MI Preliminary Results of GUSTO IV presented at European Society of Cardiology August 2000

  2. GUSTO IV ACS Trial: Therapies • Randomized to receive either: • Placebo for 48 hours • Abciximab 0.25 mg/kg bolus plus 0.125 mg/kg/min for 24 hours followed by placebo for 24 hours • Abciximab 0.25 mg/kg bolus plus 0.125 mg/kg/min for 48 hours. • All patients received aspirin and heparin • Over 900 patients received dalteparin instead of heparin in a substudy. • PCI was not allowed until 60 hours post-randomization. • CABG surgery to be delayed until 72 hours post-randomization. Preliminary Results of GUSTO IV presented at European Society of Cardiology August 2000

  3. GUSTO IV: Baseline Demographics Preliminary Results of GUSTO IV presented at European Society of Cardiology August 2000

  4. GUSTO IV: 30 Day Outcomes P = NS for all • 1.1% higher risk of death / MI among patients treated with 48 hour infusion of abciximab did not reach statistical significance Preliminary Results of GUSTO IV presented at European Society of Cardiology August 2000

  5. GUSTO IV: Bleeding Risk * P < 0.05 Preliminary Results of GUSTO IV presented at European Society of Cardiology August 2000

  6. GUSTO IV ACS Trial: Results in Troponin + Patients • Troponin-positive patients were a subgroup with particular benefit in previous 2b/3a trials • They represent a higher-risk group • Troponin results were obtained from bedside assays • No benefit observed among these high risk patients Preliminary Results of GUSTO IV presented at European Society of Cardiology August 2000

  7. GUSTO IV ACS Trial: Discussion of Negative Trial Results • Fewer interventions than in previous trials of GP 2b/3a inhibitors • Fewer than 5% of patients underwent PCI during intervention • The maintenance dose of abciximab may have been insufficient

More Related